152 related articles for article (PubMed ID: 18611435)
1. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Oct; 362(1-2):172-8. PubMed ID: 18611435
[TBL] [Abstract][Full Text] [Related]
2. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery.
Mandawgade SD; Sharma S; Pathak S; Patravale VB
Int J Pharm; 2008 Oct; 362(1-2):179-83. PubMed ID: 18652886
[TBL] [Abstract][Full Text] [Related]
3. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Nov; 364(1):119-26. PubMed ID: 18765274
[TBL] [Abstract][Full Text] [Related]
4. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity.
Aditya NP; Patankar S; Madhusudhan B; Murthy RS; Souto EB
Eur J Pharm Sci; 2010 Aug; 40(5):448-55. PubMed ID: 20493255
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
6. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
7. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation.
Patil S; Joshi M; Pathak S; Sharma S; Patravale V
J Antimicrob Chemother; 2012 Nov; 67(11):2713-6. PubMed ID: 22899802
[TBL] [Abstract][Full Text] [Related]
8. Formulation design and in vivo antimalarial evaluation of lipid-based drug delivery systems for oral delivery of β-arteether.
Memvanga PB; Préat V
Eur J Pharm Biopharm; 2012 Sep; 82(1):112-9. PubMed ID: 22609572
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.
Patil S; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2013 Oct; 455(1-2):229-34. PubMed ID: 23886650
[TBL] [Abstract][Full Text] [Related]
10. Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
Prabhu P; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2016 Sep; 511(1):473-487. PubMed ID: 27421912
[TBL] [Abstract][Full Text] [Related]
11. Effect of artemether administered alone or in combination with praziquantel to mice infected with Plasmodium berghei or Schistosoma mansoni or both.
Shu-Hua X; Utzinger J; Chollet J; Tanner M
Int J Parasitol; 2006 Jul; 36(8):957-64. PubMed ID: 16750833
[TBL] [Abstract][Full Text] [Related]
12. Changes in the visceral functions of Plasmodium berghei-infected and -uninfected rats following administration of artemether.
Akomolafe RO; Adeoshun IO; Fakunle JB; Iwalewa EO; Ayoka AO; Akanji BO
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1180-3. PubMed ID: 17184498
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration.
Borhade VB; Nair HA; Hegde DD
Drug Dev Ind Pharm; 2009 May; 35(5):619-30. PubMed ID: 18979309
[TBL] [Abstract][Full Text] [Related]
14. Teratogenicity of Artemether-Clindamycin Nanostructured Lipid Carriers in Rats.
Jain SA; Awale M; Pathak S; Vanage G; Patravale VB; Sharma S
Int J Toxicol; 2016 Jul; 35(4):420-8. PubMed ID: 27278417
[TBL] [Abstract][Full Text] [Related]
15. Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation.
Bachhav YG; Patravale VB
Int J Pharm; 2009 Jan; 365(1-2):175-9. PubMed ID: 18790032
[TBL] [Abstract][Full Text] [Related]
16. Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Chinaeke EE; Chime SA; Onyishi VI; Attama AA; Okore VC
Drug Deliv; 2015; 22(5):652-65. PubMed ID: 24479677
[TBL] [Abstract][Full Text] [Related]
17. Smart nanocrystals of artemether: fabrication, characterization, and comparative in vitro and in vivo antimalarial evaluation.
Shah SM; Ullah F; Khan S; Shah SM; de Matas M; Hussain Z; Minhas MU; AbdEl-Salam NM; Assi KH; Isreb M
Drug Des Devel Ther; 2016; 10():3837-3850. PubMed ID: 27920499
[TBL] [Abstract][Full Text] [Related]
18. Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles.
Agubata CO; Nzekwe IT; Attama AA; Mueller-Goymann CC; Onunkwo GC
Int J Pharm; 2015 Jan; 478(1):202-222. PubMed ID: 25448583
[TBL] [Abstract][Full Text] [Related]
19. An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether.
Memvanga PB; Coco R; Préat V
J Control Release; 2013 Dec; 172(3):904-13. PubMed ID: 24021359
[TBL] [Abstract][Full Text] [Related]
20. Antiplasmodial activity of Cylicodiscus gabunensis.
Okokon JE; Ita BN; Udokpoh AE
J Ethnopharmacol; 2006 Sep; 107(2):175-8. PubMed ID: 16635557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
